Zhangxin He on Muck Rack

Zhangxin He

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zhangxin

Contact Zhangxin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

De Novo Design of Efficient NIR‐II‐Activated Heavy‐Atom‐Free Type‐I Photosensitizer for Anti‐Tumor Photoimmunotherapy

|
By Huan Chen, Yu Wang, Zhangxin He, Yingpeng Wan
| Wiley Online Library Verified
Conflict of Interest The authors declare no conflict of interest. Supporting Information Filename Description adma202501919-sup-0001-SuppMat.docx22.5 MB Supporting Information References 1, , , , , Angew. Chem., Int. Ed. 2018, 57, 11522. 2, Nat. Rev. Cancer. 2003, 3, 375. 3, , , , Nat. Rev. Clin. Oncol. 2020, 17, 657. 4, , , , , , , , , , , , , Nat. Chem. 2019, 11, 1041. 5, , , , , , , , Nat. Commun. 2022, 13, 2009. 6, , , , Acc. Chem. Res. 2021, 54, 207. 7, , , , Chem. Soc. Rev. 2022, 51, 3324. 8, , , , , , , J. Am. Chem.
Open in Who Shared Issue with article?

Optimized Bionic Drug-Delivery-Inducing Immunogenic Cell Death and cGAS-STING Pathway Activation for Enhanced Photodynamic-Chemotherapy-Driven Immunotherapy in Prostate Cancer

|
By Chunchen Wu, Dexiang Feng, Hongbo Xu, Zhangxin He
| dx.doi.org
Open in Who Shared Issue with article?

Dual‐Pronged Attack: pH‐Driven Membrane‐Anchored NIR Dual‐Type Nano‐Photosensitizer Excites Immunogenic Pyroptosis and Sequester Immune Checkpoint for Enhanced Prostate Cancer Photo‐Immunotherapy

|
By He Wang, Yijian Gao, Dexiang Feng, Zhangxin He
| Wiley Online Library Verified
Abstract Prostate cancer (PCa) is a frustrating immunogenic “cold” tumor and generally receives unsatisfied immunotherapy outcomes in the clinic.
Open in Who Shared Issue with article?
See all 3 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified